338 related articles for article (PubMed ID: 10349694)
1. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients.
Maddrey WC
Semin Liver Dis; 1999; 19 Suppl 1():67-75. PubMed ID: 10349694
[TBL] [Abstract][Full Text] [Related]
2. Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients.
Scotto G; Fazio V; Palumbo E; Cibelli DC; Saracino A; Angarano G
New Microbiol; 2005 Jan; 28(1):23-9. PubMed ID: 15782623
[TBL] [Abstract][Full Text] [Related]
3. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
Samuel D; Bizollon T; Feray C; Roche B; Ahmed SN; Lemonnier C; Cohard M; Reynes M; Chevallier M; Ducerf C; Baulieux J; Geffner M; Albrecht JK; Bismuth H; Trepo C
Gastroenterology; 2003 Mar; 124(3):642-50. PubMed ID: 12612903
[TBL] [Abstract][Full Text] [Related]
4. Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.
de Lédinghen V; Trimoulet P; Winnock M; Foucher J; Bourlière M; Desmorat H; Canva V; Capron D; Lévy S; Mion F; Mannant PR; Chêne G; Fleury H; Couzigou P; Bernard PH;
J Hepatol; 2002 May; 36(5):672-80. PubMed ID: 11983451
[TBL] [Abstract][Full Text] [Related]
5. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
[TBL] [Abstract][Full Text] [Related]
6. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
McHutchison JG; Gordon SC; Schiff ER; Shiffman ML; Lee WM; Rustgi VK; Goodman ZD; Ling MH; Cort S; Albrecht JK
N Engl J Med; 1998 Nov; 339(21):1485-92. PubMed ID: 9819446
[TBL] [Abstract][Full Text] [Related]
7. Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients.
Bain VG; Kaita KD; Marotta P; Yoshida EM; Swain MG; Bailey RJ; Patel K; Cronin PW; Pulkstenis E; McHutchison JG; Subramanian GM
Clin Gastroenterol Hepatol; 2008 Jun; 6(6):701-6. PubMed ID: 18467185
[TBL] [Abstract][Full Text] [Related]
8. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group.
Glue P; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S; Clement RP
Hepatology; 2000 Sep; 32(3):647-53. PubMed ID: 10960463
[TBL] [Abstract][Full Text] [Related]
9. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients.
Neary MP; Cort S; Bayliss MS; Ware JE
Semin Liver Dis; 1999; 19 Suppl 1():77-85. PubMed ID: 10349695
[TBL] [Abstract][Full Text] [Related]
10. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.
González-Peralta RP; Kelly DA; Haber B; Molleston J; Murray KF; Jonas MM; Shelton M; Mieli-Vergani G; Lurie Y; Martin S; Lang T; Baczkowski A; Geffner M; Gupta S; Laughlin M;
Hepatology; 2005 Nov; 42(5):1010-8. PubMed ID: 16250032
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.
Meyer-Wyss B; Rich P; Egger H; Helbling B; Müllhaupt B; Rammert C; Gonvers JJ; Oneta C; Criblez D; Rossi L; Borovicka J; Meyenberger C; Arn M; Renner EL;
J Viral Hepat; 2006 Jul; 13(7):457-65. PubMed ID: 16792539
[TBL] [Abstract][Full Text] [Related]
12. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
Sostegni R; Ghisetti V; Pittaluga F; Marchiaro G; Rocca G; Borghesio E; Rizzetto M; Saracco G
Hepatology; 1998 Aug; 28(2):341-6. PubMed ID: 9695995
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2 plus ribavirin versus interferon-alpha-2b plus ribavirin in patients with chronic hepatitis C who did not respond to previous interferon-alpha-2b treatment.
Malaguarnera M; Pistone G; Neri S; Romano M; Brogna A; Musumeci S
BioDrugs; 2004; 18(6):407-13. PubMed ID: 15571424
[TBL] [Abstract][Full Text] [Related]
14. Viusid, a nutritional supplement, in combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Vilar Gomez E; Gra Oramas B; Soler E; Llanio Navarro R; Ruenes Domech C
Liver Int; 2007 Mar; 27(2):247-59. PubMed ID: 17311621
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C.
McHutchison JG; Poynard T
Semin Liver Dis; 1999; 19 Suppl 1():57-65. PubMed ID: 10349693
[TBL] [Abstract][Full Text] [Related]
16. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.
Reichard O; Norkrans G; Frydén A; Braconier JH; Sönnerborg A; Weiland O
Lancet; 1998 Jan; 351(9096):83-7. PubMed ID: 9439491
[TBL] [Abstract][Full Text] [Related]
17. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
Scott LJ; Perry CM
Drugs; 2002; 62(3):507-56. PubMed ID: 11827565
[TBL] [Abstract][Full Text] [Related]
18. Association of response to combined interferon alpha-2b and ribavirin therapy in patients of chronic hepatitis c with serum alanine aminotransferase levels and severity of the disease on liver biopsy.
Nadeem A; Hussain MM; Aslam M; Hussain T; Butt IF; Ali Khan S; Asad A
J Ayub Med Coll Abbottabad; 2009; 21(2):103-6. PubMed ID: 20524482
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing treatment efficacy of 24-week combination therapy with interferon alpha-2b plus ribavirin for chronic hepatitis C.
Moriyama M; Matsumura H; Nirei K; Arakawa Y; Yamagami H; Ogawa M; Kaneko M; Matsuoka S; Amaki S; Tanaka N; Arakawa Y
Dig Dis Sci; 2007 Sep; 52(9):2418-26. PubMed ID: 17406829
[TBL] [Abstract][Full Text] [Related]
20. Interferon alpha-2b in combination with ribavirin for the treatment of chronic hepatitis C: assessment of virological, biochemical and histological treatment response.
Petrenkiene V; Gudinaviciene I; Jonaitis L; Kupcinskas L
Medicina (Kaunas); 2004; 40(6):538-46. PubMed ID: 15208476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
